Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01514422 · ClinicalTrials.gov registry record · Phase 4

Minocycline for Bipolar Depression

A Phase 4 study of Bipolar Depression, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target
1
Study location

NCT01514422: Completed Phase 4 study of Bipolar Depression, sponsored by Icahn School of Medicine at Mount Sinai.

NCT01514422 is a Phase 4 study of Bipolar Depression that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 20 participants, below the 215-participant average among 29 other Bipolar Depression trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01514422, a Phase 4 study of Bipolar Depression, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate minocycline as a potential treatment for bipolar depression when added to a mood-stabilizing medication. Minocycline is an antibiotic that is approved for the treatment of infections and acne. Participation in this research study is expected to last 8 weeks, and includes five outpatient visits.

Primary Outcome

Measured at baseline and week 8. The MADRS-S has 10-items which are based on mood symptoms over the past 7 days. Each items is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression).

Conditions Studied

Bipolar Depression

Interventions

  • DRUG Minocycline

Study Locations (1)

New York

  • Icahn School of Medicine at Mount Sinai - New York

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2011-05
Est. Completion 2013-08
Phase Phase 4
Icahn School of Medicine at Mount Sinai

708 total trials

What the finished NCT01514422 record still lists

NCT01514422 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 215-participant average among 29 other Bipolar Depression trials with a reported enrollment target (91% lower).

The record links to 1 condition, with Bipolar Depression appearing as the primary indexed condition, and to 1 intervention - of which Minocycline is the first listed.

NCT01514422 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01514422 about?

NCT01514422 is a clinical study titled "Minocycline for Bipolar Depression". The purpose of this study is to evaluate minocycline as a potential treatment for bipolar depression when added to a mood-stabilizing medication. Minocycline is an antibiotic that is approved for the treatment of infections and acne. Participation in this research study is expected to last 8 weeks, ...

What is the current status of trial NCT01514422?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2011-05. Estimated completion is 2013-08.

What conditions does trial NCT01514422 study?

This clinical trial studies the following conditions: Bipolar Depression.

What interventions are being tested in trial NCT01514422?

The interventions under investigation include: Minocycline (DRUG).

Who is sponsoring clinical trial NCT01514422?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01514422 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Bipolar Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01514422's enrollment target sits among peer trials

20 22nd of 29 higher than 3 of 29 other Bipolar Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bipolar Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01514422, the US trial registry maintained by the National Library of Medicine. NCT01514422 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.